6600

SciClone Pharmaceuticals (Holdings) Limited, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products in the therapeutic areas of oncology and severe infection in Mainland China and internationally. The company's proprietary product is Zadaxin, which is used for the treatment of hepatitis B and hepatitis C viruses, and certain cancers, as well as for use as an immune system enhance. Its in-licensed products include Zometa for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, and hypercalcemia of malignancy; DANYELZA for the treatment of relapsed/refractory high-risk neuroblastoma; and Angiomax, an anticoagulant for use in patients undergoing percutaneous coronary intervention comprising patients with heparin-induced thrombocytopenia and thrombosis syndrome.